Side-by-side comparison of AI visibility scores, market position, and capabilities
P&G's flagship oral care brand competing with Colgate; 3D Whitestrips at-home whitening franchise dominates premium whitening segment in two-brand toothpaste market oligopoly.
Crest is Procter & Gamble's flagship oral care brand, producing toothpaste, teeth whitening products (Crest 3D Whitestrips), electric toothbrush systems (Oral-B, co-branded), mouthwash, and floss — competing with Colgate for US and global toothpaste market leadership in a two-brand oligopoly that has dominated oral care for decades. Part of Procter & Gamble (NYSE: PG), one of the world's largest consumer goods companies with approximately $84 billion in annual revenue, Crest is one of P&G's largest and most profitable brands.\n\nCrest's product architecture spans fluoride toothpaste (Crest Cavity Protection, Crest Complete), sensitivity relief (Crest Gum and Sensitivity, formulated with stannous fluoride), whitening (Crest 3D White), prescription-strength (Crest Pro-Health), and premium (Crest brilliance pro). The 3D Whitestrips at-home whitening franchise is one of the most successful category innovations in oral care — creating a premium whitening segment worth billions that Crest dominates. Crest is sold through grocery, drug, and mass merchandise retailers globally.\n\nIn 2025, Crest competes with Colgate-Palmolive (the global toothpaste market leader by volume) for oral care market share. The oral care market has seen premiumization with sensitivity and whitening products growing faster than basic fluoride toothpaste, and new entrants like Hello Products (natural positioning), Arm & Hammer (baking soda), and Sensodyne (GSK/Haleon) competing in specific benefit segments. Crest's 2025 strategy focuses on the 3D Whitestrips franchise (launching new formats and expanding internationally), growing the sensitivity relief segment, and defending against natural and premium challenger brands.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.